|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Reteplase#Nonclinical Toxicology]] |
| {{Reteplase}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Nonclinical Toxicology==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===Carcinogenesis, Mutagenesis, Impairment of Fertility:===
| | [[Category: Anticoagulants]] |
| Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Retavase.® Studies to determine mutagenicity, chromosomal aberrations, gene mutations, and micronuclei induction were negative at all concentrations tested. Reproductive toxicity studies in rats revealed no effects on fertility at doses up to 15 times the human dose (4.31 units/kg).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RETAVASE (RETEPLASE) KIT [EKR THERAPEUTICS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e9ae6656-977c-4105-8528-bee664aab27a | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |